Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 20/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 20/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 20/20 | 0.55 |
| ▸ | DYRK2 | Q92630 | 18/20 | 0.55 |
| ▸ | DYRK3 | O43781 | 18/20 | 0.55 |
| ▸ | CLK2 | P49760 | 18/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 18/20 | 0.55 |
| ▸ | CLK3 | P49761 | 17/20 | 0.55 |
| ▸ | DYRK4 | Q9NR20 | 13/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 8/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24904299 | 0.78 | CLK1 (0.62) | CLK1DYRK1ADYRK1BDYRK2DYRK3 | |
| SCHEMBL23510727 | 0.76 | CLK1 (0.63) | CLK1DYRK1ADYRK1BDYRK2DYRK3 | |
| SCHEMBL30396931 | 0.76 | CLK1 (0.63) | CLK1DYRK1ADYRK1BDYRK2DYRK3 | |
| SCHEMBL23510452 | 0.71 | CLK1 (0.54) | CLK1DYRK1ADYRK1BDYRK2DYRK3 | |
| SCHEMBL30395881 | 0.71 | CLK1 (0.60) | CLK1DYRK1ADYRK1BDYRK2DYRK3 | |
| SCHEMBL26105144 | 0.71 | CLK1 (0.60) | CLK1DYRK1ADYRK1BDYRK2DYRK3 | |
| SCHEMBL26465419 | 0.71 | CLK1 (0.49) | CLK1DYRK1ADYRK1BDYRK2DYRK3 | |
| SCHEMBL30396462 | 0.70 | DYRK2 (0.58) | CLK1DYRK1ADYRK1BDYRK2DYRK3 | |
| SCHEMBL26107592 | 0.70 | DYRK2 (0.58) | CLK1DYRK1ADYRK1BDYRK2DYRK3 | |
| SCHEMBL30145013 | 0.70 | CLK1 (1.00) | CLK1DYRK1ADYRK1BDYRK2DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TONGJI UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TNNI3, TNNT2, MKI67 | CLK1 2884/4885DYRK1A 3319/4885DYRK1B 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.